ストックスクリーナーアプリを入手
16.64
5.29%
-0.9531
前日終値:
$17.59
開ける：
$17.48
24時間の取引高:
140.71K
Relative Volume:
0.22
時価総額：
$909.11M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-0.54%
1か月 パフォーマンス:
-5.07%
6か月 パフォーマンス:
+41.30%
1年 パフォーマンス:
+39.18%
1日の値動き範囲:
$16.59
$17.96
1週間の範囲:
$15.73
$18.24
52週間の値動き範囲:
$7.80
$19.71
Bicara Therapeutics Inc Stock (BCAX) Company Profile
名前
Bicara Therapeutics Inc
セクター
電話
617-468-4219
住所
116 HUNTINGTON AVENUE SUITE 703, BOSTON
BCAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
16.59 | 963.61M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.40 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.46 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.41 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.52 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.26 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-08 | 開始されました | BTIG Research | Buy |
| 2025-12-18 | 開始されました | Mizuho | Neutral |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-05-23 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | 開始されました | Wells Fargo | Underweight |
| 2025-02-06 | 開始されました | Wedbush | Outperform |
| 2024-12-06 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-05 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 開始されました | Morgan Stanley | Overweight |
| 2024-10-08 | 開始されました | Stifel | Buy |
| 2024-10-08 | 開始されました | TD Cowen | Buy |
すべてを表示
Bicara Therapeutics Inc (BCAX) 最新ニュース
Analyst Upgrade: Should I set a stop loss on Bicara Therapeutics IncOptions Play & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Stocks To Watch: Bicara Therapeutics Sees Relative Strength Rating Rise To 81 - Investor's Business Daily
Quarterly Earnings: What are analysts price targets for Bicara Therapeutics IncVolume Spike & Real-Time Buy Signal Alerts - baoquankhu1.vn
BCAX: De-Risked FORTIFI-HN01 Path, Differentiated Ficera Profile, and Solid Cash Runway Underpin Buy Rating and $28 Target - TipRanks
Bicara Therapeutics stock maintains Buy rating at BTIG on clinical progress - Investing.com Nigeria
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), NewAmsterdam Pharma Company (NAMS) and GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
Does Bicara Therapeutics Inc align with a passive investing strategyDividend Hike & Weekly Market Pulse Updates - baoquankhu1.vn
H.C. Wainwright reiterates Buy rating on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Bicara Therapeutics stock - Investing.com
How cyclical is Bicara Therapeutics Inc.’s revenue stream2025 Market Outlook & Daily Growth Stock Investment Tips - bollywoodhelpline.com
Bicara Therapeutics (NASDAQ:BCAX) Given Outperform Rating at Wedbush - Defense World
Growth Report: Will Bicara Therapeutics Inc. stock continue upward momentumJuly 2025 Opening Moves & Weekly Breakout Watchlists - Bộ Nội Vụ
Wedbush Reaffirms Outperform Rating for Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat
Bicara selects optimal dose for head and neck cancer drug in pivotal study - Investing.com Nigeria
Bicara Therapeutics Touts Breakthrough Ficerafusp Data, Picks 1,500 mg Dose for FORTIFY-HNS Trial - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 7%Time to Sell? - MarketBeat
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook - Sahm
Bicara Sets Phase 3 Path for Ficerafusp Alfa - TipRanks
Bicara Therapeutics announces phase 3 optimal dose and provides 2026 corporate outlook - marketscreener.com
Bicara Therapeutics Inc Announces Phase 3 Optimal Dose and 2026 Outlook - TradingView — Track All Markets
Bicara Therapeutics Announces Phase 3 Optimal Dose And Provides 2026 Corporate Outlook - TradingView — Track All Markets
Published on: 2026-01-12 06:24:33 - moha.gov.vn
Bicara Therapeutics (NASDAQ:BCAX) Trading 7.8% Higher – Should You Buy? - Defense World
Is Bicara Therapeutics Inc. stock trading at a premium valuationWeekly Trade Review & Precise Trade Entry Recommendations - ulpravda.ru
BTIG Research Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc.Common Stock (NQ: BCAX - FinancialContent
Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.8%Here's Why - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Upgraded to "Strong-Buy" at BTIG Research - MarketBeat
Published on: 2026-01-09 02:43:58 - Улправда
Is Bicara Therapeutics Inc. stock a defensive play in 2025July 2025 Breakouts & Safe Entry Trade Signal Reports - Улправда
Upcoming EventsBicara Therapeutics Inc.Common Stock (Nasdaq:BCAX) Detailed Stock Data - FinancialContent
BTIG Initiates Coverage of Bicara Therapeutics (BCAX) with Buy Recommendation - Nasdaq
Los Angeles Daily NewsBicara Therapeutics Inc.Common Stock (Nasdaq:BCAX) Price Chart - FinancialContent
History Review: Can Bicara Therapeutics Inc. stock deliver sustainable ROEMarket Risk Summary & Real-Time Market Sentiment Reports - ulpravda.ru
What hedge fund activity signals for Bicara Therapeutics Inc. stockQuarterly Profit Summary & AI Based Trade Execution Alerts - Улправда
Bicara Therapeutics initiated with a Buy at BTIG - TipRanks
BTIG initiates coverage on Bicara Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
BTIG Research Initiates Coverage on Bicara Therapeutics With Buy Rating, $28 Price Target - MarketScreener
BTIG initiates coverage on Bicara Therapeutics stock with Buy rating - Investing.com
News | postregister.comBicara Therapeutics Inc.Common Stock (Nasdaq:BCAX) Stock Quote - FinancialContent
Can Bicara Therapeutics Inc. stock rebound after recent weaknessEarnings Date Calendar & Free Grow Wealth With Picks - Улправда
Bicara Therapeutics: How InvestingPro’s overvaluation call led to 39% decline By Investing.com - Investing.com South Africa
Bicara Therapeutics management to meet with Cantor Fitzgerald - MSN
Will Bicara Therapeutics Inc. stock continue dividend increases2026 world cup usa national team group stage playmakers pressing system winner prediction preview - Улправда
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of “Hold” from Analysts - Defense World
Bicara Therapeutics Inc (BCAX) 財務データ
Bicara Therapeutics Inc (BCAX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
3.30%
2.06%
大文字化:
|
ボリューム (24 時間):